Riik: Suurbritannia
keel: inglise
Allikas: VMD (Veterinary Medicines Directorate)
Clotrimazole, Dexamethasone, Marbofloxacin
Norbrook Laboratories Limited
QS02CA06
Clotrimazole, Dexamethasone, Marbofloxacin
Ear drops, suspension
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Antimicrobial
Authorized
2015-08-24
Revised: August 2020 AN: 01600/2019 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbodex Aural Ear Drops, Suspension for Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: ACTIVE SUBSTANCES: Marbofloxacin 3.0 mg Clotrimazole 10.0 mg Dexamethasone 0.9 mg (equivalent to dexamethasone acetate 1.0 mg EXCIPIENTS Propyl gallate (E310) 1.0 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Ear drops, suspension. Homogenous beige to yellow oily suspension. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of otitis externa of both bacterial and fungal origin respectively due to bacteria susceptible to marbofloxacin, and fungi especially _Malassezia _ _pachydermatis_ susceptible to clotrimazole. 4.3 CONTRAINDICATIONS Do not use in dogs suffering from perforation of the tympanic membrane. Do not use in known cases of hypersensitivity to the active substances or to any of the excipients. See section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Revised: August 2020 AN: 01600/2019 Page 2 of 6 The external ear canal should be meticulously cleaned and dried before treatment. Bacterial and fungal otitis is often secondary in nature. The underlying cause should be identified and treated. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals For external use only. Avoid contact with the eyes in animals. In case of accidental contact, rinse thoroughly with water. Heavy reliance on a single class of antibiotic may result in the induction of resistance in a bacterial population. It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antibiotics. Before treating with the product, the integrity of the tympanic membrane must be verified. Official and local antimicrobial policies should be taken into account when the product is used. See section 4.4 Quinolo Lugege kogu dokumenti